Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
Journal article
EWER K. et al, (2021), The Lancet
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm sub-study of a phase 2/3 clinical trial
Journal article
EWER K. et al, (2021), Lancet HIV
Divergent trajectories of antiviral memory after SARS-Cov-2 infection
Preprint
Tomic* A. et al, (2021)
Antibody evasion by the P.1 strain of SARS-CoV-2.
Journal article
Dejnirattisai W. et al, (2021), Cell, 184, 2939 - 2954.e9
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
Journal article
Barrett JR. et al, (2021), Nature medicine
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Journal article
Barrett JR. et al, (2021), Nature medicine
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera.
Journal article
Zhou D. et al, (2021), Cell, 184, 2348 - 2361.e6
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera.
Journal article
Supasa P. et al, (2021), Cell, 184, 2201 - 2211.e7
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
Journal article
Emary KRW. et al, (2021), Lancet, 397, 1351 - 1362
A haemagglutination test for rapid detection of antibodies to SARS-CoV-2.
Journal article
Townsend A. et al, (2021), Nat Commun, 12
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Journal article
Voysey M. et al, (2021), Lancet, 397, 881 - 891
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
Journal article
Ramasamy MN. et al, (2021), Lancet, 396, 1979 - 1993
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a Phase 1/2 clinical trial.
Journal article
LAMBE T. et al, (2020), Nature Medicine
Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
Journal article
Pollard AJ. et al, (2020), Lancet Infect Dis
Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN®-Filo Ebola vaccine regimen: a phase 2 randomised clinical study in Europe (EBOVAC2)
Journal article
POLLARD A., (2020), Lancet Infectious Diseases
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial (vol 396, pg 467, 2020)
Journal article
Folegatti P. et al, (2020), LANCET, 396, 466 - 466
Presumed Risk Factors and Biomarkers for Severe Respiratory Syncytial Virus Disease and Related Sequelae: Protocol for an Observational Multicenter, Case-Control Study From the Respiratory Syncytial Virus Consortium in Europe (RESCEU).
Journal article
Jefferies K. et al, (2020), The Journal of infectious diseases
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Journal article
HODGSON S., (2020), The Lancet
Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel
Journal article
Adams ER. et al, (2020), Wellcome Open Research, 5, 139 - 139
Immunogenicity and Reactogenicity of a Reduced Schedule of a 4-component Capsular Group B Meningococcal Vaccine: A Randomized Controlled Trial in Infants
Internet publication
Valente Pinto M. et al, (2020)